Kyoung Eun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kyoung Eun Lee has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Jee Hyun Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
8 shared publications - Hee Jun Kim
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Republic of Korea
7 shared publications - Joohyuk Sohn
Yonsei Cancer Center, Seoul, Republic of Korea
7 shared publications - Kyung-Hun Lee
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
7 shared publications - Seock-Ah Im
Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea
7 shared publications - In Sil Choi
Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer
Introduction: In the treatment of hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer (MBC), the current guidelines recommend endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors as the preferred first-line treatment to preserve quality of life. Ribociclib is a CDK4/6 inhibitor that has been used in combination with aromatase inhibitors or fulvestrant in patients with HR+, HER2− metastatic breast cancer. Various adverse drug reactions associated with ribociclib have been reported, including cutaneous reactions, hepatotoxicity, and hematologic toxicity. In this study, we aimed to evaluate the clinical manifestations and risk factors of dermatologic toxicities in patients with metastatic breast cancer treated with ribociclib. Methods: This retrospective study included patients with metastatic/recurrent breast cancer who were prescribed ribociclib from April 2021 to December 2024 at a single institution. We retrospectively reviewed the medical records of these patients to identify the frequency of cutaneous adverse events, the time of onset, and the clinical characteristics of skin reactions. Logistic regression analysis was performed on several clinical factors, including body surface area (BSA) and concomitant medications, to identify risk factors associated with the occurrence of cutaneous adverse events. Results: A total of 110 patients with MBC were enrolled during the study period. The median age was 53 years (range, 28–82); all 110 patients (100.0%) were female; the median BSA was 1.56 m2 (range, 1.29–2.07); and 32 patients (29.1%) were premenopausal. Ribociclib plus letrozole was administered in 48 patients (43.6%) and ribociclib plus fulvestrant in 29 patients (26.4%). An additional 33 patients (30.0%) received ribociclib plus letrozole with a gonadotropin-releasing hormone (GnRH) agonist. Cutaneous adverse events occurred in 29 patients (26.4%), and the median time to onset was 84 days (range, 3–498). The cutaneous adverse event patterns included pruritus, erythematous macular rash, eczematous rash/contact dermatitis, vitiligo, urticarial reactions, polymorphous light eruption, toxic epidermal necrolysis (TEN), and desquamation. Grade 1 or 2 cutaneous adverse events occurred in 93.1% of patients; Grade 3 toxicity occurred in one patient; and Grade 4 toxicity, namely toxic epidermal necrolysis (TEN), was reported in one patient. Dose reduction was required in three patients (10.3%), and permanent discontinuation of ribociclib occurred in one patient. Clinical improvement was achieved in the majority of patients (86.2%) with cutaneous adverse events following supportive care. Logistic regression analysis revealed that age, Eastern Cooperative Oncology Group (ECOG) performance status, body surface area (BSA), treatment regimen, and use of cholesterol-lowering medications were not independently associated with the development of cutaneous adverse events. Conclusion: CDK4/6 inhibitors represent one of the most important treatment options for HR+/HER2− metastatic breast cancer. Regardless of their clinical efficacy, cutaneous adverse events remain a common source of patient discomfort. Therefore, careful clinical attention and appropriate supportive care are essential to improve patients' quality of life.
Open AccessAnalysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer
Introduction: In the treatment of hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer (MBC), the current guidelines recommend endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors as the preferred first-line treatment to preserve quality of life. Ribociclib is a CDK4/6 inhibitor that has been used in combination with aromatase inhibitors or fulvestrant in patients with HR+, HER2− metastatic breast cancer. Various adverse drug reactions associated with ribociclib have been reported, including cutaneous reactions, hepatotoxicity, and hematologic toxicity. In this study, we aimed to evaluate the clinical manifestations and risk factors of dermatologic toxicities in patients with metastatic breast cancer treated with ribociclib. Methods: This retrospective study included patients with metastatic/recurrent breast cancer who were prescribed ribociclib from April 2021 to December 2024 at a single institution. We retrospectively reviewed the medical records of these patients to identify the frequency of cutaneous adverse events, the time of onset, and the clinical characteristics of skin reactions. Logistic regression analysis was performed on several clinical factors, including body surface area (BSA) and concomitant medications, to identify risk factors associated with the occurrence of cutaneous adverse events. Results: A total of 110 patients with MBC were enrolled during the study period. The median age was 53 years (range, 28–82); all 110 patients (100.0%) were female; the median BSA was 1.56 m2 (range, 1.29–2.07); and 32 patients (29.1%) were premenopausal. Ribociclib plus letrozole was administered in 48 patients (43.6%) and ribociclib plus fulvestrant in 29 patients (26.4%). An additional 33 patients (30.0%) received ribociclib plus letrozole with a gonadotropin-releasing hormone (GnRH) agonist. Cutaneous adverse events occurred in 29 patients (26.4%), and the median time to onset was 84 days (range, 3–498). The cutaneous adverse event patterns included pruritus, erythematous macular rash, eczematous rash/contact dermatitis, vitiligo, urticarial reactions, polymorphous light eruption, toxic epidermal necrolysis (TEN), and desquamation. Grade 1 or 2 cutaneous adverse events occurred in 93.1% of patients; Grade 3 toxicity occurred in one patient; and Grade 4 toxicity, namely toxic epidermal necrolysis (TEN), was reported in one patient. Dose reduction was required in three patients (10.3%), and permanent discontinuation of ribociclib occurred in one patient. Clinical improvement was achieved in the majority of patients (86.2%) with cutaneous adverse events following supportive care. Logistic regression analysis revealed that age, Eastern Cooperative Oncology Group (ECOG) performance status, body surface area (BSA), treatment regimen, and use of cholesterol-lowering medications were not independently associated with the development of cutaneous adverse events. Conclusion: CDK4/6 inhibitors represent one of the most important treatment options for HR+/HER2− metastatic breast cancer. Regardless of their clinical efficacy, cutaneous adverse events remain a common source of patient discomfort. Therefore, careful clinical attention and appropriate supportive care are essential to improve patients' quality of life.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Table S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Table S2 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Table S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Table S3 from Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
- Open Access
- 1 September 2025
- Published by Korean Society of Medical Education in Korean Journal of Medical Education
- Vol. 37 (3) , 345-353
The moderating effect of team-based learning participation frequency on the relationship between medical students’ perception of systematic team-based learning class management and active class participation
Purpose: This study aimed to examine the moderating effect of team-based learning (TBL) participation frequency on the relationship between medical students’ perception of the systematic management of TBL classes and their active class participation.Methods: To achieve this purpose, feedback data from 575 students who participated in TBL-based courses at Ewha Womans University College of Medicine during the second semester of the 2022 academic year and the first semester of the 2023 academic year were analyzed. Descriptive statistics, correlation analysis and moderation analysis were conducted.Results: The results of the study are as follows. First, students’ perception of systematic TBL class management showed a significant positive correlation with active class participation. Second, the frequency of TBL participation was found to play a moderating role in the relationship between the perception of systematic TBL class management and active class participation.Conclusion: This study highlights that both systematic TBL class management and the frequency of participation are key factors in promoting student engagement in medical education. Based on these findings, educational implications are discussed.
- 1 September 2025
- Published by Korean Society of Medical Education in Korean Journal of Medical Education
- Vol. 37 (3) , 345-353
Open AccessThe moderating effect of team-based learning participation frequency on the relationship between medical students’ perception of systematic team-based learning class management and active class participation
Purpose: This study aimed to examine the moderating effect of team-based learning (TBL) participation frequency on the relationship between medical students’ perception of the systematic management of TBL classes and their active class participation.Methods: To achieve this purpose, feedback data from 575 students who participated in TBL-based courses at Ewha Womans University College of Medicine during the second semester of the 2022 academic year and the first semester of the 2023 academic year were analyzed. Descriptive statistics, correlation analysis and moderation analysis were conducted.Results: The results of the study are as follows. First, students’ perception of systematic TBL class management showed a significant positive correlation with active class participation. Second, the frequency of TBL participation was found to play a moderating role in the relationship between the perception of systematic TBL class management and active class participation.Conclusion: This study highlights that both systematic TBL class management and the frequency of participation are key factors in promoting student engagement in medical education. Based on these findings, educational implications are discussed.
- 20 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (21) , 4586-4597
Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Purpose: PD-1/PD-L1 blockade modulates the responses of T cells, including regulatory T cells (Treg). Understanding the changes of Treg upon PD-1/PD-L1 blockade in patients with cancer and their association with therapeutic response will provide clues about the mechanisms underlying resistance to treatment. Experimental Design: Peripheral blood samples were acquired before and at 1 week following treatment from 65 patients [triple-negative (TN), n = 35; luminal, n = 30] enrolled in the KORNELIA phase II trial, which evaluated the efficacy of chemoimmunotherapy combining nivolumab and eribulin in patients with HER2-negative breast cancer. The immunophenotype of circulating immune cells was analyzed by flow cytometry. T-cell receptor sequencing was used to track the clonotypes of circulating Treg in relation to the tumor-related clonotypes. Results: In both breast cancer subtypes, chemoimmunotherapy increased the proportion of circulating Treg as well as their proliferative response. Notably, we observed an increased frequency of the circulating Treg population with tumor-related clonotypes after treatment in triple-negative breast cancer (TNBC). Moreover, increased proliferation of circulating Treg was associated with poor response to treatment, only in TNBC. This association between circulating Treg proliferation and poor clinical response was further supported by the analysis of publicly available single-cell transcriptomic data from patients with TNBC. A Treg-based biomarker predicted both clinical response and survival outcomes in TNBC. Conclusions: Our results indicate that the proliferation and expansion of tumor-related clonotypes among circulating Treg are related to chemoimmunotherapy resistance, particularly in TNBC.
- 20 August 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (21) , 4586-4597
Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer
Purpose: PD-1/PD-L1 blockade modulates the responses of T cells, including regulatory T cells (Treg). Understanding the changes of Treg upon PD-1/PD-L1 blockade in patients with cancer and their association with therapeutic response will provide clues about the mechanisms underlying resistance to treatment. Experimental Design: Peripheral blood samples were acquired before and at 1 week following treatment from 65 patients [triple-negative (TN), n = 35; luminal, n = 30] enrolled in the KORNELIA phase II trial, which evaluated the efficacy of chemoimmunotherapy combining nivolumab and eribulin in patients with HER2-negative breast cancer. The immunophenotype of circulating immune cells was analyzed by flow cytometry. T-cell receptor sequencing was used to track the clonotypes of circulating Treg in relation to the tumor-related clonotypes. Results: In both breast cancer subtypes, chemoimmunotherapy increased the proportion of circulating Treg as well as their proliferative response. Notably, we observed an increased frequency of the circulating Treg population with tumor-related clonotypes after treatment in triple-negative breast cancer (TNBC). Moreover, increased proliferation of circulating Treg was associated with poor response to treatment, only in TNBC. This association between circulating Treg proliferation and poor clinical response was further supported by the analysis of publicly available single-cell transcriptomic data from patients with TNBC. A Treg-based biomarker predicted both clinical response and survival outcomes in TNBC. Conclusions: Our results indicate that the proliferation and expansion of tumor-related clonotypes among circulating Treg are related to chemoimmunotherapy resistance, particularly in TNBC.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of the Korean Society of Radiology
- Vol. 85 (6) , 1169-1182
Sudden Development of Fatal Pulmonary due to Suspected Pulmonary Tumoral Thrombotic Microangiopathy among Patients with Cancer: Case Series of Clinical and CT Features in 10 Patients
김보경, et al. J Korean Soc Radiol. 2024 Nov;85(6):1169-1182. https://doi.org/10.3348/jksr.2024.0084
- 1 January 2024
- Published by XMLink in Journal of the Korean Society of Radiology
- Vol. 85 (6) , 1169-1182
Open AccessSudden Development of Fatal Pulmonary due to Suspected Pulmonary Tumoral Thrombotic Microangiopathy among Patients with Cancer: Case Series of Clinical and CT Features in 10 Patients
김보경, et al. J Korean Soc Radiol. 2024 Nov;85(6):1169-1182. https://doi.org/10.3348/jksr.2024.0084
- Open Access
- 14 October 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 195, 113386
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
- 14 October 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 195, 113386
Open AccessClinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)